---
title: "CG: Record earnings, strong fundraising, and $485B AUM highlight a robust Q2 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294946210.md"
description: "Q2 2026 saw record Fee Related Earnings and the highest Distributable Earnings in nearly four years, with strong fundraising, realization activity, and $485 billion in AUM. Dividend of $0.35 per share was declared, and $304 million in shares were repurchased.Original document: The Carlyle Group Inc. [CG] Slides Release — Aug. 5 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-05T10:06:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294946210.md)
  - [en](https://longbridge.com/en/news/294946210.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294946210.md)
generator: "portal-rs"
---

# CG: Record earnings, strong fundraising, and $485B AUM highlight a robust Q2 2026

Q2 2026 saw record Fee Related Earnings and the highest Distributable Earnings in nearly four years, with strong fundraising, realization activity, and $485 billion in AUM. Dividend of $0.35 per share was declared, and $304 million in shares were repurchased.

Original document: The Carlyle Group Inc. \[CG\] Slides Release — Aug. 5 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [CG.US](https://longbridge.com/en/quote/CG.US.md)

## Related News & Research

- [Carlyle Group Inc. Buys New Stake in Krispy Kreme, Inc. $DNUT](https://longbridge.com/en/news/296197289.md)
- [Carlyle Q2 FY26 net income attributable to common stockholders drops to $137.1 million; revenue falls to $1.12 billion](https://longbridge.com/en/news/294945308.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [ROI-Three midweek thoughts — dodging AI, uber bulls and intervention flub: Mike Dolan](https://longbridge.com/en/news/296308398.md)
- [EGTX: Q2 2026 revenue up 23% YoY; U.S. Emcitate launch expected Q4 2026 pending FDA approval](https://longbridge.com/en/news/296636890.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**